COMP <GO>
ALNY vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ALNY 3
— JNJ 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: ALNY
LAST: $165.00 (-5.17%) • MKT CAP: $23.28B
options-implied-move
6.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 67.90% | +13.90 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 25.50% | -4.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 18.5x | +23.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 2.97% | -0.97 | JNJ | /fcf-yield <GO> |
| Operating Margin | 13.50% | 34.70% | -21.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 28.50% | -20.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | 6.00% | +59.20 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 5.59 | -2.43 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.20% | -0.30 | ALNY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.1 | 60.4 | -38.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 23.0x | +39.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.28B | $662.49B | -$639.21B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | JNJ REV | ALNY GROSS % | JNJ GROSS % | ALNY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $94.19B | 81.8% | 67.9% | $465.4M | $19.70B |
| FY 2024 | $2.25B | $88.82B | 86.4% | 69.1% | -$42.6M | $19.84B |
| FY 2023 | $1.83B | $85.16B | 44.0% | 44.0% | $21.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
JNJ // BETA 1.08